FACULTY
Agustin Garcia
CHIEF OF MEDICAL ACADEMIC AREA
Med-Hematology and oncology
- agarc6@lsuhsc.edu
- Medicine
Academic Office:
LSUHSC School of Medicine
1700 Tulane Av, Room 502
New Orleans, LA 70112
Clinical Office:
University Medical Center, Cancer Center
2001 Tulane Avenue
New Orleans, LA 70112
Bio
Dr. Agustin Garcia is originally from Mexico and earned his Medical Degree from Universidad Anahuac in Mexico City. He completed his internship and residency training in Internal Medicine at the University of Illinois and a Fellowship in Medical Oncology at the University of Southern California. He is board certified in Medical Oncology. Dr. Garcia's primary clinical and research interests focus on women’s cancers (particularly breast and ovarian cancer) and drug development. Prior to relocating to New Orleans he practiced at the University of Southern California as Director of Clinical Research for the Women’s Cancer Program. He currently serves as Section Chief of Hematology and Oncology at Louisiana State University in New Orleans where he holds the Charles W McMullin III and Richard Paul Grace Chair in Cancer Research. Dr. Garcia is a member of the Breast Cancer Working Group and the Breast Cancer Committee in the Southwest Oncology Group and the Ovarian Cancer Committee of the NRG Oncology Group. He is conducting studies in breast and ovarian cancer evaluating new agents with novel mechanisms of action. He is a member of the American Society of Clinical Oncology, American Society of Breast Disease, European Society of Medical Oncology, and the NCI Task Force on Cervical Cancer. His work has been published in various journals such as the New England Journal of Medicine, Journal of Clinical Oncology and Gynecologic Oncology. He is a frequent speaker at local, national and international events.
Education
Medical:
M.D.
Universidad Anahuac
Mexico City, Mexico
Residency:
Internal Medicine
University of Ilinois at Urbana Champaign
Champaign County, Illinios
Fellowship:
Oncology
University of Southern California
Los Angeles, California
Graduate:
Masters in Medical Management
University of Southern California
Los Angeles, California
Affiliated Hospitals & Clinics
- University Medical Center
- East Jefferson General Hospital
- Lallie Kemp Regional Medical Center
- West Jefferson Medical Center
Publications
1. Pahlawanian AM, Norris VA, Jernigan AM, Morrell B, Morrell M, Nair N, Karamanis AM,
Dauchy EM, Loch MM, Garcia AA. An Update on Screening and Prevention for Breast and Gynecological Cancers in Average
and High Risk Individuals. Am J Med Sci. 2020 Nov;360(5):489-510. doi: 10.1016/j.amjms.2020.06.008. Epub 2020 Jun 10. Review. PubMed PMID: 32912601.
2. Wu AH, Tseng C, Vigen C, Yu Y, Cozen W, Garcia AA, Spicer D. Gut microbiome associations with breast cancer risk factors and tumor characteristics:
a pilot study. Breast Cancer Res Treat. 2020 Jul;182(2):451-463. doi: 10.1007/s10549-020-05702-6. Epub 2020 May 28. PubMed PMID: 32468338; PubMed Central PMCID: PMC7297869.
3. Kumthekar P, Tang SC, Brenner AJ, Kesari S, Piccioni DE, Anders C, Carrillo J, Chalasani
P, Kabos P, Puhalla S, Tkaczuk K, Garcia AA, Ahluwalia MS, Wefel JS, Lakhani N, Ibrahim N. ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with
Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases. Clin Cancer Res. 2020 Jun 15;26(12):2789-2799. doi: 10.1158/1078-0432.CCR-19-3258. Epub 2020 Jan 22. PubMed PMID: 31969331.
4. Coyne GO', Wang L, Zlott J, Juwara L, Covey JM, Beumer JH, Cristea MC, Newman EM,
Koehler S, Nieva JJ, Garcia AA, Gandara DR, Miller B, Khin S, Miller SB, Steinberg SM, Rubinstein L, Parchment RE,
Kinders RJ, Piekarz RL, Kummar S, Chen AP, Doroshow JH. Intravenous 5-fluoro-2'-deoxycytidine administered with tetrahydrouridine increases
the proportion of p16-expressing circulating tumor cells in patients with advanced
solid tumors. Cancer Chemother Pharmacol. 2020 May;85(5):979-993. doi: 10.1007/s00280-020-04073-5. Epub 2020 Apr 20. PubMed PMID: 32314030; PubMed Central PMCID: PMC7188725.
5. Vergote I, Powell MA, Teneriello MG, Miller DS, Garcia AA, Mikheeva ON, Bidzinski M, Cebotaru CL, Dutcus CE, Ren M, Kadowaki T, Funahashi Y,
Penson RT. Second-line lenvatinib in patients with recurrent endometrial cancer. Gynecol Oncol. 2020 Mar;156(3):575-582. doi: 10.1016/j.ygyno.2019.12.039. Epub 2020 Jan 17. PubMed PMID: 31955859.
6. Blake EA, Bradley CA, Mostofizadeh S, Muggia FM, Garcia AA, Roman LD, Matsuo K. Efficacy of pegylated liposomal doxorubicin maintenance therapy in platinum-sensitive
recurrent epithelial ovarian cancer: a retrospective study. Arch Gynecol Obstet. 2019 Jun;299(6):1641-1649. doi: 10.1007/s00404-019-05104-0. Epub 2019 Mar 1. PubMed PMID: 30824986; PubMed Central PMCID: PMC7521082.
7. Moore HCF, Unger JM, Phillips KA, Boyle F, Hitre E, Moseley A, Porter DJ, Francis
PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow JR, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian LM,
Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS. Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup
S0230. J Natl Cancer Inst. 2019 Feb 1;111(2):210-213. doi: 10.1093/jnci/djy185. PubMed PMID: 30371800; PubMed Central PMCID: PMC6657277.
8. Rustin G, Vergote I, Micha JP, Duska LR, Reed N, Bendell J, Spitz D, Dark G, Hoch
U, Tagliaferri M, Hannah AL, Garcia AA. A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy
of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent
platinum-resistant or refractory ovarian cancer. Gynecol Oncol. 2017 Nov;147(2):276-282. doi: 10.1016/j.ygyno.2017.08.026. Epub 2017 Sep 19. PubMed PMID: 28935273.
9. Somlo G, Frankel PH, Arun BK, Ma CX, Garcia AA, Cigler T, Cream LV, Harvey HA, Sparano JA, Nanda R, Chew HK, Moynihan TJ, Vahdat
LT, Goetz MP, Beumer JH, Hurria A, Mortimer J, Piekarz R, Sand S, Herzog J, Van Tongeren
LR, Ferry-Galow KV, Chen AP, Ruel C, Newman EM, Gandara DR, Weitzel JN. Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in
Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res. 2017 Aug 1;23(15):4066-4076. doi: 10.1158/1078-0432.CCR-16-2714. Epub 2017 Mar 29. PubMed PMID: 28356425; PubMed Central PMCID: PMC5540749.
10. Connolly RM, Li H, Jankowitz RC, Zhang Z, Rudek MA, Jeter SC, Slater SA, Powers P,
Wolff AC, Fetting JH, Brufsky A, Piekarz R, Ahuja N, Laird PW, Shen H, Weisenberger
DJ, Cope L, Herman JG, Somlo G, Garcia AA, Jones PA, Baylin SB, Davidson NE, Zahnow CA, Stearns V. Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat:
A Phase II National Cancer Institute/Stand Up to Cancer Study. Clin Cancer Res. 2017 Jun 1;23(11):2691-2701. doi: 10.1158/1078-0432.CCR-16-1729. Epub 2016 Dec 15. PubMed PMID: 27979916; PubMed Central PMCID: PMC5457329.
Research
Title: Enabling A Paradigm Shift: A Preference-Tolerant RCT of Personalized vs Annual Screening
of Breast Cancer. SPEC-18-006
Sponsor: BCRF via Quantum Leap Healthcare Collaborative
Role: Local Primary Investigator
Dates: 10/01/2018-12/30/2019
Title: IGF-2 in Herceptin refractory HER2-positive breast cancer
Sponsor: METAvivor Founders Award
Role: Co-Investigator. (Bolin L)
Title: Differential effects of diet on normal and malignant tissues
Sponsor: Obesity / Cancer Pilot and Feasibility Grant sponsored by the Pennington Nutrition
Obesity Research Center (NORC) and LSU HSC-NO Cancer Center
Role: Co-Investigator. (Gilmore A, Kern L)
Dates: 2017-2019
Title: Extending the Diversity, Reach, and Generalizability of the WISDOM Study. R01 PA-18-559
.
Sponsor: NIH
Role: Co-Investigator. (Esserman)
Dates: 09/01/2019-8/31/2024
Clinical Trials
Title: A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic
Response in Patients with Clinical/Radiologic Complete Response After Neoadjuvant
Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment Without
Surgery.
Sponsor: NCI
Title: A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability
of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer.
Sponsor: Seattle Genetics
Title: Testing if docetaxel or paclitaxel induces less peripheral neuropathy in African American
women
Sponsor: NCI
Title: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with
Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
Sponsor: NCI
Title: (CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a
Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive
Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast
Cancer)
Sponsor: NCI
Title: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize
Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded,
Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
Sponsor: NCI
Title: A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818, a Dual Receptor
Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects with
Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical
Carcinoma
Sponsor: Advenchen
Title: A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous
Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or
Persistent Cervical Carcinoma
Sponsor: Iovance Therapeutics
Title: Testing the Addition of Two Approved Drugs, Olanzapine or Prochlorperazine, for Persistent
Nausea
Sponsor: NCI
Title: A Prospective Observational Cohort Study to Develop A Predictive Model of Taxane-Induced
Peripheral Neuropathy in Cancer Patients
Sponsor: NCI